These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

691 related items for PubMed ID: 22950547

  • 1. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
    Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, Woolacott N.
    Pharmacoeconomics; 2012 Nov 01; 30(11):991-1004. PubMed ID: 22950547
    [Abstract] [Full Text] [Related]

  • 2. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
    Norman G, Faria R, Paton F, Llewellyn A, Fox D, Palmer S, Clifton I, Paton J, Woolacott N, McKenna C.
    Health Technol Assess; 2013 Nov 01; 17(52):1-342. PubMed ID: 24267198
    [Abstract] [Full Text] [Related]

  • 3. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years.
    Walker S, Burch J, McKenna C, Wright K, Griffin S, Woolacott N.
    Health Technol Assess; 2011 May 01; 15 Suppl 1():13-21. PubMed ID: 21609649
    [Abstract] [Full Text] [Related]

  • 4. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I, Stevenson M, Cooper K, Harnan S, Hamilton J, Clowes M, Carroll C, Harrison T, Saha S.
    Pharmacoeconomics; 2018 Feb 01; 36(2):131-144. PubMed ID: 28933002
    [Abstract] [Full Text] [Related]

  • 5. Omalizumab for the treatment of severe persistent allergic asthma.
    Jones J, Shepherd J, Hartwell D, Harris P, Cooper K, Takeda A, Davidson P.
    Health Technol Assess; 2009 Sep 01; 13 Suppl 2():31-9. PubMed ID: 19804687
    [Abstract] [Full Text] [Related]

  • 6. Reslizumab for Treating Asthma with Elevated Blood Eosinophils Inadequately Controlled by Inhaled Corticosteroids: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Cooper K, Frampton G, Harris P, Rose M, Chorozoglou M, Pickett K.
    Pharmacoeconomics; 2018 May 01; 36(5):545-553. PubMed ID: 29582406
    [Abstract] [Full Text] [Related]

  • 7. Omalizumab for asthma in adults and children.
    Normansell R, Walker S, Milan SJ, Walters EH, Nair P.
    Cochrane Database Syst Rev; 2014 Jan 13; 2014(1):CD003559. PubMed ID: 24414989
    [Abstract] [Full Text] [Related]

  • 8. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.
    Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce IN, Sculpher M, Woolacott N.
    Pharmacoeconomics; 2012 Apr 13; 30(4):257-70. PubMed ID: 22283690
    [Abstract] [Full Text] [Related]

  • 9. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.
    Faria R, McKenna C, Palmer S.
    Value Health; 2014 Dec 13; 17(8):772-82. PubMed ID: 25498772
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective.
    Levy AN, García A Ruiz AJ, García-Agua Soler N, Sanjuan MV.
    J Asthma; 2015 Mar 13; 52(2):205-10. PubMed ID: 24995661
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
    Wade R, Duarte A, Simmonds M, Rodriguez-Lopez R, Duffy S, Woolacott N, Spackman E.
    Pharmacoeconomics; 2015 May 13; 33(5):457-66. PubMed ID: 25616671
    [Abstract] [Full Text] [Related]

  • 15. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal.
    Rodgers M, Griffin S, Paulden M, Slack R, Duffy S, Ingram JR, Woolacott N, Sculpher M.
    Pharmacoeconomics; 2010 May 13; 28(5):351-62. PubMed ID: 20131924
    [Abstract] [Full Text] [Related]

  • 16. Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.
    Wade R, Rose M, Neilson AR, Stirk L, Rodriguez-Lopez R, Bowen D, Craig D, Woolacott N.
    Pharmacoeconomics; 2013 Oct 13; 31(10):841-52. PubMed ID: 23996108
    [Abstract] [Full Text] [Related]

  • 17. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
    Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W.
    Ann Intern Med; 2011 May 03; 154(9):573-82. PubMed ID: 21536936
    [Abstract] [Full Text] [Related]

  • 18. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.
    Bagust A, Greenhalgh J, Boland A, Fleeman N, McLeod C, Dickson R, Dundar Y, Proudlove C, Shaw R.
    Pharmacoeconomics; 2010 May 03; 28(6):439-48. PubMed ID: 20465313
    [Abstract] [Full Text] [Related]

  • 19. The role of omalizumab in the treatment of severe allergic asthma.
    Chapman KR, Cartier A, Hébert J, McIvor RA, Schellenberg RR.
    Can Respir J; 2006 May 03; 13 Suppl B(Suppl B):1B-9B. PubMed ID: 16909166
    [Abstract] [Full Text] [Related]

  • 20. Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pouwels XGLV, Wolff R, Ramaekers BLT, Van Giessen A, Lang S, Ryder S, Worthy G, Duffy S, Armstrong N, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2018 May 03; 36(5):533-543. PubMed ID: 29344794
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.